NCT04114136 2025-02-10
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
University of Pittsburgh
Phase 2 Recruiting
Clinical Trials
11 trialsNCT00004180 2023-06-26
Rosiglitazone in Treating Patients With Liposarcoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01019356 2022-01-20
Role of Insulin Action and Free Fatty Acids in Hyperandrogenism of Women With Polycystic Ovary Syndrome
Université de Sherbrooke
Phase NA Completed
NCT00616642 2020-08-14
Rosiglitazone in Treating Patients With Pituitary Tumors
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT00640224 2017-11-17
Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study
University of Pittsburgh
Phase 4 Completed
NCT03309319 2017-10-13
A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas
Huashan Hospital
Phase NA Unknown
NCT02475499 2016-03-14
Incretin-based Drugs and Pancreatic Cancer
Canadian Network for Observational Drug Effect Studies, CNODES
Completed
NCT00933309 2016-02-19
The Impact of Obesity and Obesity Treatments on Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00178841 2016-02-17
Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL
Vanderbilt University
Phase 2 Completed
NCT00084578 2013-07-15
Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder
Fox Chase Cancer Center
Phase NA Withdrawn
NCT00182052 2013-05-23
Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer
Massachusetts General Hospital
Phase 3 Completed